Who is sponsoring NCT03549351?

NCT03549351 is sponsored by University Hospital Heidelberg.

What drugs are being tested in NCT03549351?

Interventions in NCT03549351: Measurable residual disease measured by flow cytometry.

What condition does NCT03549351 study?

NCT03549351 studies Leukemia, Myeloid, Acute.

Is NCT03549351 still recruiting?

NCT03549351 is currently terminated. Last updated 13 September 2022.

Last reviewed 2022-09-13 · How we verify

NCT03549351: PERDAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Terminated Last updated 13 September 2022

What this trial tests

trial testing Measurable residual disease measured by flow cytometry in Leukemia, Myeloid, Acute in 51 participants. Terminated before completion.

Timeline

1 June 2019

Primary endpoint
11 September 2022

11 September 2022

Quick facts

Lead sponsor	University Hospital Heidelberg
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	51
Start date	1 June 2019
Primary completion	11 September 2022
Estimated completion	11 September 2022
Sites	1 location across Germany

Drugs / interventions tested

Measurable residual disease measured by flow cytometry

Conditions studied

Leukemia, Myeloid, Acute — all drugs for Leukemia, Myeloid, Acute →

Sponsor

University Hospital Heidelberg

Who can join

Eligibility, any sex, with Leukemia, Myeloid, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design Surrogate endpoint trial to establish that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL, Ravandi F, Patel KP, Short NJ. · · 2021 · cited 40× · PMID 34479626 · DOI 10.1186/s13045-021-01148-5
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Meddi E, Savi A, Moretti F, Mallegni F, et al · · 2023 · cited 12× · PMID 36834477 · DOI 10.3390/ijms24043062

Verify or expand the search:

Other recruiting trials for Leukemia, Myeloid, Acute

Currently open trials in the same condition.

NCT06852222 — A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke · Phase 3 · recruiting
NCT06651229 — A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
NCT06618001 — A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
NCT06643962 — Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearan · NA · recruiting
NCT06382168 — DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03549351 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 13 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing